Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0757
D

Duplicate Proton Pump Inhibitor Therapy Administered Without Clinical Justification

Rancho Mirage, California Survey Completed on 04-24-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to ensure that a resident’s drug regimen was free from unnecessary medications when two proton pump inhibitors (PPIs), pantoprazole 40 mg in the morning and omeprazole 20 mg at bedtime, were ordered and administered daily for the same indication of gastroesophageal reflux disease (GERD). Review of the resident’s medical record and Medication Administration Record (MAR) showed both medications were given concurrently from March 22 through April 23, with no documented clinical rationale for the duplicate therapy. The orders for both PPIs were initiated on the same date, and the administration was verified by the Director of Nursing (DON), who acknowledged that both drugs are from the same therapeutic class and have similar mechanisms of action. The facility’s Consultant Pharmacist (CP) confirmed that he had not reviewed these medications since they were ordered after his last medication regimen review. The CP stated he would have questioned the duplicate use and recommended discontinuing one of the PPIs if there was no clinical justification. Facility policy requires staff to contact the prescriber if a medication is believed to be inappropriate or excessive, but there was no evidence this was done. Prescribing information and national guidelines indicate that the two PPIs are considered equivalent for GERD treatment and that there is no benefit to administering both simultaneously.

An unhandled error has occurred. Reload 🗙